Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
65 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Cervical Intraepithelial Neoplasia (CIN) - Pipeline Review, H2 2015', provides an overview of the Cervical Intraepithelial Neoplasia (CIN)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cervical Intraepithelial Neoplasia (CIN), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cervical Intraepithelial Neoplasia (CIN) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cervical Intraepithelial Neoplasia (CIN) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cervical Intraepithelial Neoplasia (CIN) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cervical Intraepithelial Neoplasia (CIN) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cervical Intraepithelial Neoplasia (CIN) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cervical Intraepithelial Neoplasia (CIN) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Cervical Intraepithelial Neoplasia (CIN) Overview 6 Therapeutics Development 7 Pipeline Products for Cervical Intraepithelial Neoplasia (CIN) - Overview 7 Cervical Intraepithelial Neoplasia (CIN) - Therapeutics under Development by Companies 8 Cervical Intraepithelial Neoplasia (CIN) - Pipeline Products Glance 9 Clinical Stage Products 9 Cervical Intraepithelial Neoplasia (CIN) - Products under Development by Companies 10 Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development 11 CEL-SCI Corporation 11 Helix BioPharma Corp. 12 Inovio Pharmaceuticals, Inc. 13 PDS Biotechnology Corporation 14 Vaccibody AS 15 Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment 16 Assessment by Monotherapy Products 16 Assessment by Target 17 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Drug Profiles 25 GLBL-101c - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 interferon alpha-2b (recombinant) - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Leukocyte Interleukin - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 PDS-0101A - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 VB-1016 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 VGX-3100 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Cervical Intraepithelial Neoplasia (CIN) - Recent Pipeline Updates 36 Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects 52 Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products 53 Cervical Intraepithelial Neoplasia (CIN) - Product Development Milestones 54 Featured News & Press Releases 54 Sep 17, 2015: Inovio Pharmaceuticals Publishes Successful Phase 2b Trial Results of Its HPV Immunotherapy in The Lancet 54 Jul 23, 2014: Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 55 Jun 11, 2014: Inovio Pharmaceuticals Clarifies Facts of its VGX-3100 Phase II Trial and Immunotherapy Technology 56 Feb 11, 2014: PDS Biotechnology Announces Treatment of First Patient with PDS0101 based on the Novel Versamune Cancer Immunotherapy Platform in a Phase 1 Clinical Trial 57 Oct 10, 2012: Inovio Pharma's DNA-based Therapeutic Cancer Vaccine Produces Immune Responses To Kill Target Cells In Phase I Study 58 May 01, 2012: Inovio Receives US Patent Protection For Synthetic Vaccine For Cervical Dysplasia And Cancer 59 Nov 11, 2011: FDA Removes Clinical Hold For Helix's Topical Interferon Alpha-2b Phase II/III Efficacy Trial IND Application 60 Oct 31, 2011: Fierce Vaccines Highlights Inovio's Cervical Dysplasia And Cancer Vaccine As One Of 10 Promising Therapeutic Vaccines 60 Oct 05, 2011: Inovio's Synthetic Vaccine for Cancer Recognized As Most Promising Research at Global Vaccine Congress 61 Jul 15, 2011: Inovio Demonstrates T Cell Immune Response From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine 62 Appendix 64 Methodology 64 Coverage 64 Secondary Research 64 Primary Research 64 Expert Panel Validation 64 Contact Us 64 Disclaimer 65
List of Tables
Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H2 2015 7 Number of Products under Development by Companies, H2 2015 8 Comparative Analysis by Clinical Stage Development, H2 2015 9 Products under Development by Companies, H2 2015 10 Cervical Intraepithelial Neoplasia (CIN) - Pipeline by CEL-SCI Corporation, H2 2015 11 Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Helix BioPharma Corp., H2 2015 12 Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015 13 Cervical Intraepithelial Neoplasia (CIN) - Pipeline by PDS Biotechnology Corporation, H2 2015 14 Cervical Intraepithelial Neoplasia (CIN) - Pipeline by Vaccibody AS, H2 2015 15 Assessment by Monotherapy Products, H2 2015 16 Number of Products by Stage and Target, H2 2015 18 Number of Products by Stage and Mechanism of Action, H2 2015 20 Number of Products by Stage and Route of Administration, H2 2015 22 Number of Products by Stage and Molecule Type, H2 2015 24 Cervical Intraepithelial Neoplasia (CIN) Therapeutics - Recent Pipeline Updates, H2 2015 36 Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects, H2 2015 52 Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products, H2 2015 53
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
